Cover Image

市場進入的課題:腎細胞癌 (歐盟5國)

Market Access Impact: Renal Cell Carcinoma (EU5)

出版商 FirstWord 商品編碼 358503
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
市場進入的課題:腎細胞癌 (歐盟5國) Market Access Impact: Renal Cell Carcinoma (EU5)
出版日期: 2016年05月01日 內容資訊: 英文

本報告由以歐盟5國 (法國·義大利·德國·西班牙·英國) 150名癌症專門醫生為對象所進行的腎細胞癌治療藥的處方趨勢調查結果,得出給付,價格等主要8品牌的市場進入障礙·影響因素之比較分析及個別分析,並彙整其對市場佔有率的影響等資訊。


  • 各種障礙對打入市場的影響
    • 醫生最大量開處方的品牌為何?
    • 受各種障礙影響的處方箋數為何?
    • 哪個障礙最影響大?
  • 障礙對各品牌的影響
    • 醫生對各品牌的處方數為何?不打算再開處方的數為何?
    • 醫生不開處方的理由為何?替代其開處方的藥物為何?
    • 被競爭品牌奪走的佔有率有多少?


  • Afinitor
  • Avastin
  • Inlyta
  • Nexavar
  • Proleukin
  • Sutent
  • Torisel
  • Votrient
Product Code: 596200688

Market barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand one of them?

We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European market when oncologists can't prescribe freely. The result: 5 of those brands saw a net loss.

But 3 of them made significant net gains. Is your brand one of them?

You'll learn how market barriers affect share for 8 major treatments from Bayer/Amgen, Novartis, Pfizer, and Roche.

Plus you'll see which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.

Get Answers to Key Questions about RCC Drug Brands

  • Afinitor (everolimus; Novartis): Afinitor takes market share from only two brands. Which two?
  • Avastin (bevacizumab; Roche): Which brand takes more than twice as much share from Avastin as any other?
  • Inlyta (axitinib; Pfizer): Would eliminating market barriers help Inlyta catch up to Afinitor?
  • Nexavar (sorafenib; Bayer/Amgen): Are doctors who don't prescribe either brand more likely to consider Nexavar or Inlyta?
  • Proleukin (aldesleukin; Novartis): Which two barriers do more doctors experience with Proleukin than any other brand?
  • Sutent (sunitinib; Pfizer): Which barrier is responsible for nearly a quarter of Sutent's impressive share gain?
  • Torisel (temsirolimus; Pfizer): Only one market barrier earns Torisel a net share gain. Which one?
  • Votrient (pazopanib; Novartis): Votrient and Afinitor are just about equally prescribed. Which brand has the edge in market share?

Top Takeaways

  • Barriers cost most brands market share: Five of the eight surveyed brands saw a net share loss due to barriers. Only three saw net gains.
  • Eliminating barriers would tighten up the market: Especially the top of the market, where it would make a big dent in the #1 brand's lead.
  • Most brands are heavily prescribed: A majority of doctors prescribe nearly all of the brands surveyed. The most prescribed brand has almost a 10% lead over its nearest rival.
  • Clear market share winner: of the three brands that gain share due to market barriers, one gains more than twice as much as the closest competitor.
  • Barrier effect varies widely: The number of doctors who experience each market barrier varies widely from brand to brand.
  • Reimbursement and guidelines have the greatest impact: barriers related to reimbursement, patient type restrictions, and guidelines affect more prescriptions than any others.
  • Brand awareness is high: With one exception, no more than 1% of doctors surveyed were unaware of any given brand.
  • Overall market access is good: In Europe, market barriers affect less than 20% of prescription decisions.

Exploring Market Access Issues

Market Access Impact: RCC explores key issues affecting RCC drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest effect?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 medical oncologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between April 4th and 11th, 2016.

Back to Top